Happy Nice Mall

Without solid data on the long-term effectiveness of the Johnson & Johnson vaccine, it’s difficult for health officials to recommend boosters, said John Moore, a virologist at Weill Cornell Medicine. “If you’re making data-driven decisions and you don’t have the data, what can you do?” said. “It’s kind of a dilemma. Public confidence in vaccines often depends on seeing how the sausage is made, a data-driven, transparent process.”

How effective is the Johnson & Johnson vaccine?

Clinical trials conducted before the delta variant became widespread, showed that the Johnson & Johnson vaccine had 72 percent effectiveness In the United States overall, lower roughly 95 percent effectiveness Pfizer and Moderna vaccines. However, direct comparisons between vaccines tried in different places and at different times are difficult.

All current vaccines seem to lose some effectiveness against Delta, which can circumvent some of the immune system’s antibodies. The Johnson & Johnson vaccine is no exception. Dr. “You’d expect some degree of resistance to Delta, because there’s always been,” Moore said.

Small lab studies have produced conflicting results about how well the Johnson & Johnson vaccine protects against Delta. Last month, Johnson & Johnson said that a single dose of the vaccine induces a strong immune response to Delta and the response lasts for at least eight months.

But the data another new lab study suggested that a single dose of the vaccine elicits a relatively weak antibody response to Delta, which may make boosters more necessary.

The first real-world data on the effectiveness of the vaccine against the variant were released this month. Preliminary data from a clinical trial of nearly 500,000 healthcare workers in South Africa suggested that a single dose of the vaccine was effective. efficiency up to 96 percent against death, 71 percent against hospitalization from infections caused by Delta.

It’s a “one shot J.&J. A virologist at Beth Israel Deaconess Medical Center in Boston who conducted studies for Johnson & Johnson but was not involved in the South African trial. Dan Barouch said the vaccine provides significant protection against the Delta variant.